Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma

by Thanh Hung Nguyen, Frederic G. Barr
Published 2018-10-01

Evidence of pioneer factor activity of an oncogenic fusion transcription factor

by Benjamin D. Sunkel, Meng Wang, Stephanie LaHaye, Benjamin J. Kelly, James R. Fitch, Frederic G. Barr, Peter White, Benjamin Z. Stanton
Published 2021-08-01

Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: Utility and pitfalls

by Ashley R.P. Hinson, Rosanne eJones, Lisa E.S. Crose, Brian eBelyea, Frederic G. Barr, Corinne M. Linardic, Corinne M. Linardic
Published 2013-07-01

Clonality and evolutionary history of rhabdomyosarcoma.

by Li Chen, Jack F Shern, Jun S Wei, Marielle E Yohe, Young K Song, Laura Hurd, Hongling Liao, Daniel Catchpoole, Stephen X Skapek, Frederic G Barr, Douglas S Hawkins, Javed Khan
Published 2015-03-01

Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Onco...

by Emily Hibbitts, Yueh‐Yun Chi, Douglas S. Hawkins, Frederic G. Barr, Julie A. Bradley, Roshni Dasgupta, William H. Meyer, David A. Rodeberg, Erin R. Rudzinski, Sheri L. Spunt, Stephen X. Skapek, Suzanne L. Wolden, Carola A. S. Arndt
Published 2019-10-01

Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity

by Gabriele Manzella, Leonie D. Schreck, Willemijn B. Breunis, Jan Molenaar, Hans Merks, Frederic G. Barr, Wenyue Sun, Michaela Römmele, Luduo Zhang, Joelle Tchinda, Quy A. Ngo, Peter Bode, Olivier Delattre, Didier Surdez, Bharat Rekhi, Felix K. Niggli, Beat W. Schäfer, Marco Wachtel
Published 2020-09-01